HC Wainwright Predicts Higher Earnings for Spyglass Pharma

Spyglass Pharma, Inc. (NASDAQ:SGP) – Investment analysts at HC Wainwright raised their Q2 2026 EPS estimates for shares of Spyglass Pharma in a research report issued to clients and investors on Monday, March 30th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.47) per share for the quarter, up from their prior forecast of ($0.49). HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. HC Wainwright also issued estimates for Spyglass Pharma’s Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($2.16) EPS.

Other equities research analysts have also issued research reports about the company. Citigroup started coverage on Spyglass Pharma in a research note on Tuesday, March 3rd. They set a “buy” rating and a $42.00 price target on the stock. Leerink Partners downgraded Spyglass Pharma to a “market perform” rating in a research note on Tuesday, March 3rd. Stifel Nicolaus began coverage on Spyglass Pharma in a report on Tuesday, March 3rd. They set a “buy” rating and a $42.00 price objective for the company. Zacks Research upgraded Spyglass Pharma to a “hold” rating in a research report on Wednesday, March 4th. Finally, Wall Street Zen downgraded Spyglass Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Spyglass Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $45.00.

Spyglass Pharma Stock Performance

Shares of SGP opened at $24.44 on Wednesday. Spyglass Pharma has a twelve month low of $20.16 and a twelve month high of $32.44.

Spyglass Pharma (NASDAQ:SGP) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($5.72) EPS for the quarter, beating the consensus estimate of ($6.61) by $0.89.

Insider Transactions at Spyglass Pharma

In other Spyglass Pharma news, Director Ra Capital Management, L.P. purchased 3,690,000 shares of Spyglass Pharma stock in a transaction on Monday, February 9th. The shares were bought at an average price of $16.00 per share, with a total value of $59,040,000.00. Following the completion of the acquisition, the director directly owned 5,966,439 shares of the company’s stock, valued at approximately $95,463,024. This trade represents a 162.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Spyglass Pharma Company Profile

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).